For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Please save the date for the 2022 Annual Spring Meeting of Participants which will be held in a virtual format again this year from Friday, April 29 to Sunday, May, 01.
The virtual spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
The Audit Group Team Leader will lead the Audit Team at CCTG to coordinate and implement audits of external participating clinical sites, external vendors and of internal processes to ensure compliance with applicable guidelines, regulations, standards and contractual requirements.
The Canadian Cancer Society (CCS) has launched its inaugural Data Transformation Grants to help transform cancer data and improve care. Apply for up to $125K for a 1-year project, from a funding envelope of ~$1M.
Reporting and accountable to the Manager, Early Drug Development Program (EDDP), the Trial Team Leader will lead one of several teams in Trial Management Group (TMG). Teams are comprised primarily of study coordinators, research associates, and clinical trials assistants, who are involved in the coordination of clinical trials in cancer therapy, prevention and supportive care.
Reporting to the Team Leader, Ethics and Regulatory, the Ethics Research Associate will assist to conduct the ethics responsibilities of the Ethics and Regulatory (ER) office, within the Canadian Cancer Trials Group (CCTG).
CRAFT - A Proposed Framework for Decentralized Clinical Trials Participation in Canada has been published in Current Oncology and is available online:
